Tesamorelin
Tesamorelin is a growth hormone releasing peptide used in evidence-based, physician-supervised protocols. First-line when visceral fat reduction is the primary GH peptide goal alongside GH optimization.
What is Tesamorelin?
Stabilized GHRH analogue (trans-3-hexenoic acid modification). FDA-approved for HIV-associated lipodystrophy. Stimulates GHRH-R for GH pulse; has specific effect on reducing visceral adipose tissue. Administer before bedtime — GH pulse during sleep is most physiologically relevant.
Uses & clinical decision logic
First-line when visceral fat reduction is the primary GH peptide goal alongside GH optimization. Strong clinical data on abdominal fat reduction.
Tesamorelin dosage & administration
| Vial size | BAC water | Dosing range | Units / dose | Frequency | Route |
|---|---|---|---|---|---|
| 5mg | 0.5mL | 1-2mg | 10-20 units | 5 days on / 2 off | SubQ |
| 10mg | 1mL | 1-2mg | 10-20 units | 5 days on / 2 off | SubQ |
Safety & contraindications
Active cancer contraindication; monitor glucose — may cause mild insulin resistance at higher GH levels. Monitor IGF-1.
Stacking & combinations
Pair with Ipamorelin for GHRH+GHRP synergy; compatible with GLP-1 agents for maximal visceral fat reduction.
Related peptides
Frequently asked questions
What is Tesamorelin used for?
First-line when visceral fat reduction is the primary GH peptide goal alongside GH optimization. Strong clinical data on abdominal fat reduction.
What is the typical Tesamorelin dosage?
Common dosing ranges from 1-2mg (5 days on / 2 off, SubQ). Exact dosing is individualized and set by a licensed physician.
How is Tesamorelin administered?
Tesamorelin is typically administered via SubQ.
What are the contraindications for Tesamorelin?
Active cancer contraindication; monitor glucose — may cause mild insulin resistance at higher GH levels. Monitor IGF-1.
Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.
Build your protocol →This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.